Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E34.71 EPS (ttm)2.33 Insider Own0.06% Shs Outstand2.66B Perf Week2.32%
Market Cap215.01B Forward P/E15.44 EPS next Y5.23 Insider Trans-52.57% Shs Float2.60B Perf Month7.07%
Income6.22B PEG3.65 EPS next Q1.08 Inst Own77.90% Short Float1.33% Perf Quarter5.79%
Sales42.29B P/S5.08 EPS this Y29.20% Inst Trans-0.10% Short Ratio2.61 Perf Half Y16.77%
Book/sh12.18 P/B6.63 EPS next Y11.75% ROA1.60% Target Price82.52 Perf Year48.07%
Cash/sh3.86 P/C20.91 EPS next 5Y9.51% ROE4.00% 52W Range52.83 - 80.19 Perf YTD5.71%
Dividend2.20 P/FCF13438.11 EPS past 5Y-1.90% ROI8.70% 52W High0.72% Beta0.63
Dividend %2.72% Quick Ratio1.20 Sales past 5Y-3.20% Gross Margin68.10% 52W Low52.89% ATR1.26
Employees69000 Current Ratio1.40 Sales Q/Q4.50% Oper. Margin12.00% RSI (14)70.13 Volatility1.16% 1.67%
OptionableYes Debt/Eq0.73 EPS Q/Q- Profit Margin3.20% Rel Volume0.60 Prev Close79.83
ShortableYes LT Debt/Eq0.61 EarningsFeb 01 BMO Payout377.30% Avg Volume13.24M Price80.77
Recom1.70 SMA205.32% SMA506.52% SMA20016.41% Volume7,925,865 Change1.18%
Oct-16-18Reiterated Citigroup Buy $70 → $79
Oct-09-18Resumed Guggenheim Buy
Apr-23-18Upgrade Goldman Neutral → Buy
Apr-17-18Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-05-18Upgrade Barclays Equal Weight → Overweight $62 → $64
Mar-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Feb-14-18Reiterated Leerink Partners Mkt Perform $67 → $66
Feb-07-18Reiterated Morgan Stanley Equal-Weight $60 → $63
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Feb-22-19 07:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $7.7 million of Shares GuruFocus.com
05:08PM  Merck to Buy Immunotherapy Developer Immune Design for $300M Zacks
09:21AM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
09:04AM  Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates Zacks
07:41AM  Dow 30 Stock Roundup: WMT Earnings Beat, MRK's Keytruda sBLA Gets Priority Review Zacks
Feb-21-19 01:51PM  ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Immune Design Corp. PR Newswire
10:10AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Immune Design Corp. to Merck & Co., Inc. for $5.85 Per Share is Fair to Shareholders GlobeNewswire
09:28AM  Merck To Buy Immune Design For $300M Benzinga
09:12AM  Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks
08:20AM  Immune Design (IMDZ) Alert: Johnson Fistel Investigates Proposed Sale of Immune Design Corp.; Are Immune Design Shareholders Getting a Fair Deal? PR Newswire
07:14AM  Merck to buy immunotherapy developer Immune Design for $300 mln Reuters
06:45AM  Merck to Acquire Immune Design Business Wire
Feb-20-19 11:58AM  Edited Transcript of MRK earnings conference call or presentation 1-Feb-19 1:00pm GMT Thomson Reuters StreetEvents
09:15AM  Why Merck (MRK) is a Top Dividend Stock for Your Portfolio Zacks
08:39AM  Merck's Keytruda Fails to Meet Endpoint in Liver Cancer Study Zacks
08:11AM  Intercept Reports Positive Top-Line Data for NASH, Shares Up Zacks
08:02AM  Merck expands Mass. reach with Torque cancer collaboration American City Business Journals
07:55AM  Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial TheStreet.com
07:34AM  The Daily Biotech Pulse: Teva Settles With FTC, Setback For Merck In Liver Cancer Trial, Sienna Biopharma Offering Benzinga
07:20AM  New Research: Key Drivers of Growth for DISH Network, Avon Products, Merck & Co., Laredo Petroleum, Health Insurance Innovations, and Bruker Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC) Business Wire
Feb-19-19 07:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $10. ... GuruFocus.com
05:07PM  Merck's Keytruda fails late-stage study in liver cancer patients Reuters
04:33PM  Merck's Keytruda fails late-stage study in liver cancer patients Reuters
04:29PM  Merck stock falls in late trading on cancer study MarketWatch
04:10PM  Merck Provides Update on KEYNOTE-240, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Advanced Hepatocellular Carcinoma Business Wire
09:02AM  Merck's (MRK) Stock Up Almost 50% in a Year: Here's Why Zacks
07:17AM  Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster Motley Fool
06:45AM  FDA Approves Mercks KEYTRUDA® (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection Business Wire
Feb-18-19 11:48AM  A Look At The Fair Value Of Merck & Co., Inc. (NYSE:MRK) Simply Wall St.
08:10AM  Merck Gets Priority Review for Keytruda Combo in Kidney Cancer Zacks
Feb-16-19 05:10PM  Merck, Pfizer drug combo extends kidney cancer survival -study Reuters
05:00PM  KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC) Business Wire
Feb-15-19 04:07PM  Merck Sharp & Dohme Corp. -- Moody's announces completion of a periodic review of ratings of Merck & Co., Inc. Moody's
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Advanced Renal Cell Carcinoma Business Wire
06:30AM  Cerecor Announces CERC-301 Granted U.S. Patent GlobeNewswire
Feb-14-19 01:49PM  Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat Zacks
10:50AM  The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia Zacks
09:45AM  Merck to further study Keytruda in prostate cancer after early success Reuters
08:58AM  AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales Zacks
07:34AM  [$$] Cyber Daily: Bumpy Road to NotPetya Insurance Payouts; Espionage in Iran The Wall Street Journal
06:45AM  Merck Increases Focus on Advanced Prostate Cancer, Expanding Immuno-Oncology Program with Three New Phase 3 Trials Business Wire
05:04AM  AstraZeneca Surges as Oncology Sales Drive Q4 Earnings Beat, Solid 2019 Outlook TheStreet.com
Feb-13-19 01:37PM  Top Research Reports for ExxonMobil, Merck & Danaher Zacks
Feb-12-19 06:29PM  Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100 Zacks
05:57PM  Bristol-Myers' Sprycel Gets European Nod for Label Expansion Zacks
05:50PM  Dash for NASH trips up Gilead, but 'fatty liver disease' remains biotech target American City Business Journals
05:30PM  Seattle Genetics' Adcetris Gets EC Nod for Label Expansion Zacks
03:34PM  Jeff Auxier Comments on Merck & Co. GuruFocus.com
10:10AM  Pfizer sBLA for Kidney Cancer Drug Combo Gets Priority Review Zacks
09:38AM  Stock Market News For Feb 12, 2019 Zacks
09:28AM  Positive Data for Merck's Keytruda Opens Growth Avenue Morningstar
09:12AM  Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks
Feb-11-19 08:01PM  Merck, Pfizer combo treatment boosts kidney cancer survival Reuters
05:03PM  Exclusive: Kilroy's high-profile biotech project ready to go vertical American City Business Journals
05:02PM  Merck Highlights Breadth of Immuno-Oncology Research Program in Genitourinary Cancers at ASCO GU Business Wire
03:38PM  Jeff Auxier's Winter 2018 Market Commentary GuruFocus.com
09:29AM  ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up Zacks
06:45AM  FDA Grants Priority Review to Mercks Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Business Wire
Feb-10-19 05:37PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials Benzinga
Feb-08-19 04:33PM  Incyte Down as FDA Extends Review Period of Jakafi for GVHD Zacks
03:58PM  Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark Zacks
07:51AM  Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs Zacks
07:29AM  Dow 30 Stock Roundup: Disney Earnings Impress, Pfizer's Cancer Drug Gets CHMP Nod Zacks
Feb-07-19 02:00PM  Prior dengue infection may protect against Zika - study Reuters
Feb-06-19 06:15PM  Merck & Co Inc (MRK) Chairman, President & CEO Kenneth C Frazier Sold $18. ... GuruFocus.com
03:13PM  GlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:47AM  Glaxo Inks Deal With Merck KGaA to Co-Develop Cancer Candidate Zacks
06:08AM  Winners & Losers from Trump's State of the Union Address Zacks
Feb-05-19 04:10PM  Merck CEO Frazier to testify at Senate drug pricing hearing Reuters
03:44PM  Here's Why Codexis Gained as Much as 9.8% Today Motley Fool
10:59AM  Market Update: May Back to Brussels, BP Gushes Oil, Iron Spike, Pain Feels Pain Market Exclusive
10:34AM  GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy Reuters
10:08AM  Merck Is Named No. 1 Pharma Pick at Bank of America TheStreet.com
09:19AM  Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer Zacks
07:48AM  Merck named the best pharma stock by Bank of America CNBC
07:47AM  The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results Benzinga
06:45AM  FDA Accepts for Review New Drug Application (NDA) for Mercks Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam) Business Wire
Feb-04-19 09:37AM  Stock Market News For Feb 4, 2019 Zacks
09:15AM  Why Merck (MRK) is a Great Dividend Stock Right Now Zacks
08:23AM  Better Buy: Johnson & Johnson vs. Merck & Co. Motley Fool
06:45AM  European Medicines Agency Adopts Positive Opinion for Mercks KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Adults with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Business Wire
05:35AM  10 Stocks That May Get Burned by Climate Change Investopedia
Feb-02-19 06:18PM  4 Things You Need to Know About Merck's Q4 Earnings Results Motley Fool
12:42PM  Dow and S&P Hold on to Slim Gains While Amazon Drags Nasdaq Into the Red TheStreet.com
Feb-01-19 09:46PM  Merck & Co. (MRK) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:58PM  Warren Buffett's Market Indicator Rises Near 135% GuruFocus.com
04:46PM  Merck Tops Q4 Earnings, Guides for Solid 2019, as Keytruda Sales Pass $2 Billion TheStreet.com
02:19PM  Wall Street Green on Positive Jobs Report GuruFocus.com
12:13PM  Merck News: MRK Stock Moves Higher on Q4 Earnings Beat InvestorPlace
10:58AM  Merck's Keytruda tops $2 billion in quarterly sales, shares rise Reuters
10:43AM  Exxon Mobil beats on Q4, changes at HPE, Tesla makes Model 3 changes Yahoo Finance
09:58AM  Merck 4Q net powered by cancer treatment sales, lower taxes Associated Press
09:49AM  Merck (MRK) Beats on Q4 Earnings & Sales as Keytruda Shines Zacks
09:44AM  Dow's 3 earnings reporters adding nearly 40 points to the rally MarketWatch
08:42AM  Merck (MRK) Tops on Q4 Earnings & Sales, Stock Up Zacks
06:57AM  Merck tops profit and sales estimates in latest quarter MarketWatch
06:52AM  Merck's quarterly sales rise 5.4 pct on Keytruda strength Reuters
06:45AM  Merck Announces Fourth-Quarter and Full-Year 2018 Financial Results Business Wire
03:20AM  Stocks - Amazon, Cigna Sink in Premarket, Exxon, Merck, Honeywell, Symantec Rise Investing.com
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; cholesterol modifying medicines; and anti-bacterial and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Pfizer Inc.; AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; IO Biotech; Premier Inc.; Cue Biopharma, Inc.; Foundation Medicine, Inc.; Daiichi Sankyo Company, Limited; Cold Genesys, Inc.; Kyn Therapeutics; Adlai Nortye Ltd.; Cocrystal Pharma, Inc.; and Instituto Butantan. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, distributors, veterinarians, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FRAZIER KENNETH CChairman, President & CEOFeb 22Option Exercise39.2953,9612,120,128745,911Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 22Sale80.0253,9614,318,089691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Option Exercise39.2941,9921,649,866733,942Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 21Sale80.0041,9923,359,452691,950Feb 22 05:16 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Option Exercise39.2942,7001,677,683734,650Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 19Sale80.0242,7003,416,944691,950Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Option Exercise39.2992,9133,650,552784,863Feb 19 05:35 PM
FRAZIER KENNETH CChairman, President & CEOFeb 15Sale80.0392,9137,436,162691,950Feb 19 05:35 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Option Exercise59.1664,6623,825,55180,837Feb 14 06:02 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale78.9664,6625,105,95116,175Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Option Exercise24.305,000121,5005,100Feb 14 06:02 PM
WEEKS WENDELL PDirectorFeb 13Sale78.715,000393,548100Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Option Exercise38.1873,7272,815,241125,194Feb 14 06:02 PM
Chattopadhyay SanatExe V-P & Pres. MMDFeb 12Sale78.6273,7275,796,30651,467Feb 14 06:02 PM
BRUN LESLIE ADirectorFeb 08Option Exercise24.305,000121,5005,000Feb 11 05:33 PM
BRUN LESLIE ADirectorFeb 08Sale77.223,052235,6811,948Feb 11 05:33 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Option Exercise39.29231,5669,098,228923,516Feb 06 05:30 PM
FRAZIER KENNETH CChairman, President & CEOFeb 05Sale78.08231,56618,079,654691,950Feb 06 05:30 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Option Exercise44.98225,44310,140,426366,998Nov 08 04:31 PM
PERLMUTTER ROGER MExe V-P & Pres, MRLNov 08Sale75.27225,44316,967,967141,555Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Option Exercise54.6836,2181,980,40082,481Nov 08 04:31 PM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyNov 07Sale75.1436,2182,721,34846,263Nov 08 04:31 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Option Exercise39.29277,87910,917,866277,879Nov 02 04:44 PM
Schechter Adam HEVP & Pres-Global Human HealthNov 01Sale73.81277,87920,510,9450Nov 02 04:44 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Option Exercise58.3647,0362,745,21756,806Nov 01 05:07 PM
Watson AshleySVP Chief Ethics & Com OfficerOct 31Sale74.3347,0363,496,1589,770Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Option Exercise34.1925,467870,71782,135Nov 01 05:07 PM
DeLuca Richard R.EVP&Pres, Merck Animal HealthOct 30Sale72.0025,4671,833,73956,668Nov 01 05:07 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Option Exercise36.56279,85010,231,316971,800Oct 03 05:26 PM
FRAZIER KENNETH CChairman, President & CEOOct 02Sale72.07279,85020,168,258691,950Oct 03 05:26 PM
Merck & Co., Inc.10% OwnerOct 01Buy15.00666,6669,999,9902,723,509Oct 02 02:31 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Option Exercise36.56279,85110,231,353971,801Sep 19 05:43 PM
FRAZIER KENNETH CChairman, President & CEOSep 18Sale70.08279,85119,611,818691,950Sep 19 05:43 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Option Exercise36.56100,0003,656,000100,000Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.187,360516,51155,406Sep 18 04:49 PM
Schechter Adam HEVP & Pres-Global Human HealthSep 17Sale70.18100,0007,017,7800Sep 18 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Option Exercise34.8629,2081,018,17680,675Aug 06 04:49 PM
Chattopadhyay SanatExe V-P & Pres. MMDAug 03Sale65.2029,2081,904,36251,467Aug 06 04:49 PM
Karachun Rita ASr. VP Fince-Global ControllerAug 02Sale65.015,000325,04016,175Aug 02 05:07 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Option Exercise33.49228,0917,638,768938,788Aug 01 05:12 PM
FRAZIER KENNETH CChairman, President & CEOJul 31Sale65.00228,09114,826,691710,697Aug 01 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Option Exercise36.56100,0003,656,000100,000Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.0034,0942,079,78562,766Jun 19 10:55 AM
Schechter Adam HEVP & Pres-Global Human HealthJun 18Sale61.00100,0006,100,1600Jun 19 10:55 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 15Sale59.669,972594,96345,717May 16 12:33 PM
Watson AshleySVP Chief Ethics & Com OfficerMay 01Option Exercise0.0010,441012,783May 02 12:19 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 01Option Exercise0.004,009052,609May 02 12:18 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 01Option Exercise0.003,007022,205May 02 12:18 PM
GRADDICK WEIR MIRIAN MExe V-P, HRApr 16Sale58.0024,0001,392,00080,433Apr 17 05:56 PM